Nicholas Sitaras

Nicholas Sitaras

Auto-generated profile, based on publicly available information

Nicholas Sitaras

Department of Ophthalmology, Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, Quebec H1T 2M4, Canada

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2016 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
PBPablo Federico Barcelona
Pablo Federico Barcelona
NSNicholas Sitaras
Nicholas Sitaras
AGAlba Galan
Alba Galan
GEGema Esquiva
Gema Esquiva
SJSean Jmaeff
Sean Jmaeff
HSH. Uri Saragovi
H. Uri Saragovi
In many diseases, expression and ligand-dependent activity of the p75NTR receptor can promote pericyte and vascular dysfunction, inflammation, glial activation, and neurodegeneration. Diabetic retinopathy (DR) is characterized by all of these pathological events. However, the mechanisms by which p75NTR may be implicated at each stage of DR pathology remain poorly understood. Using a streptozotocin mouse model of diabetic retinopathy, we report that p75NTR is upregulated very early in glia and in pericytes to mediate ligand-dependent induction of inflammatory cytokines, disruption of the neuro-glia-vascular unit, promotion of blood–retina barrier breakdown, edema, and neuronal death. In a mouse model of oxygen-induced retinopathy, mimicking proliferative DR, p75NTR-dependent inflammation leads to ischemia and pathological angiogenesis through Semaphorin 3A. The acute use of antagonists of p75NTR or antagonists of the ligand proNGF suppresses each distinct phase of pathology, ameliorate disease, and prevent disease progression. Thus, our study documents novel disease mechanisms and validates druggable targets for diabetic retinopathy. SIGNIFICANCE STATEMENT Diabetic retinopathy (DR) affects an estimated 250 million people and has no effective treatment. Stages of progression comprise pericyte/vascular dysfunction, inflammation, glial activation, and neurodegeneration. The pathophysiology of each stage remains unclear. We postulated that the activity of p75NTR may be implicated. We show that p75NTR in glia and in pericytes mediate ligand-dependent induction of inflammatory cytokines, disruption of the neuro-glia-vascular unit, promotion of blood–retina barrier breakdown, edema, and neuronal death. p75NTR-promoted inflammation leads to ischemia and angiogenesis through Semaphorin 3A. Antagonists of p75NTR or antagonists of proNGF suppress each distinct phase of pathology, ameliorate disease, and prevent disease progression. Our study documents novel mechanisms in a pervasive disease and validates druggable targets for treatment.

1 October 2012 in Canadian Journal of Diabetes
Verified
Journal Article
Closed access
ACAgustin Cerani
Agustin Cerani
NTNicolas Tetreault
Nicolas Tetreault
FBFrancois Binet
Francois Binet
FRFlavio Rezende
Flavio Rezende
NSNicholas Sitaras
Nicholas Sitaras
PSPrzemyslaw (Mike) Sapieha
Przemyslaw (Mike) Sapieha